Article Sidebar

PDF
Date Published: 15/01/2024
Abstract Views: 113
Views PDF: 106
DOI: https://doi.org/10.51298/vmj.v534i1.8092
Issue
Vol. 534 No. 1 (2024)
Section
Các bài báo
How to Cite
Nguyễn, T. N. H. ., & Nguyễn, D. H. . (2024). CURRENT STATUS OF NON RESPONSE TO ADALIMUMAB IN ANKYLOSING SPONDYLITIS MANAGEMENT. Vietnam Medical Journal, 534(1). https://doi.org/10.51298/vmj.v534i1.8092

CURRENT STATUS OF NON RESPONSE TO ADALIMUMAB IN ANKYLOSING SPONDYLITIS MANAGEMENT

Thị Như Hoa Nguyễn, Duy Hiệp Nguyễn

Main Article Content

Abstract

Aims: To determine the prevalence of non - response to  adalimumab and other factors related to the non – response to adalimumab in Ankylosing spondylitis patients. Subjects and methods: longitudinal, descriptive study in patients received adalimumab in Ankylosing spondylitis at Bach Mai Hospital from August 2018 to August 2022. Results: In this study of 35 ankylosing spondylitis patients (80,0% male, 27,9 ± 11,8 years of age), the percentages of primary lack of response (PLR) was 8,6% and secondary lack of response (SLR) - 14,3% respectively. Conclusions: The percentage of non - response to adalimumab in our Ankylosing spondylitis patients was 22,9%. No correlation was found between non - response to adalimumab and male sex, older age, disease duration, peripheral arthritis, HLA B27, ASDAS-CRP, medication non-adherence, concomitant methotrexat of ankylosing spondylitis patients under adalimumab.

Article Details

References

1. Ulus Y, Akyol Y, Bilgici A, Kuru O. Association of work instability with fatigue and emotional status in patients with ankylosing spondylitis: comparison with healthy controls. Clin Rheumatol. 2019; 38(4):1017-1024. doi:10.1007/s10067-018-4366-x
2. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Care Res. 2019;71(10): 1285-1299. doi:10.1002/ acr. 24025
3. Liu W, Wu Y hao, Zhang L, et al. Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis. Sci Rep. 2016;6:32768. doi:10.1038/srep32768
4. Deodhar A, Yu D. Switching tumor necrosis factor inhibitors in the treatment of axial spondyloarthritis. Semin Arthritis Rheum. 2017;47(3):3 43-350. doi:10.1016/ j.semarthrit. 2017.04.005
5. Alazmi M, Sari I, Krishnan B, Inman RD, Haroon N. Profiling Response to Tumor Necrosis Factor Inhibitor Treatment in Axial Spondyloarthritis. Arthritis Care Res. 2018;70(9): 1393-1399. doi: 10.1002/acr.23465
6. Wang R, Dasgupta A, Ward MM. Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing Spondylitis. JAMA Netw Open. 2022;5(3): e222312. doi: 10.1001/ jamanetworkopen. 2022.2312
7. Kneepkens EL, Wei JCC, Nurmohamed MT, et al. Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks of follow-up. Ann Rheum Dis. 2015;74(2): 396-401. doi: 10.1136/annrheumdis-2013-204185